Retatrutide

Retatrutide (development code LY3437943) is a synthetic, fatty-acid-modified single-chain peptide developed by Eli Lilly. It is a triple agonist: it activates the GIP, GLP-1 and glucagon receptors. It is an investigational compound, and the material sold here is a research reagent.

No. As of October 2026 retatrutide has not been approved by the FDA for any use. Eli Lilly has reported Phase 3 clinical-trial results and announced plans to file for approval, but until the FDA approves it, retatrutide remains an investigational compound.

Both are synthetic, fatty-acid-modified peptides developed by Eli Lilly. Tirzepatide is a dual agonist of the GIP and GLP-1 receptors and is an FDA-approved active ingredient. Retatrutide (LY3437943) is a triple agonist that also activates the glucagon receptor, and as of October 2026 it remains investigational and is not FDA approved. The material sold here, in either case, is a research reagent.

Retatrutide was characterized in preclinical studies in cell and rodent models examining how a single peptide engages the GIP, GLP-1 and glucagon receptors together. It has since been investigated in Phase 2 and Phase 3 clinical trials sponsored by Eli Lilly, in adults with obesity and in people with type 2 diabetes. Trial results are for the sponsor and regulators to evaluate; findings in cells or animals do not establish effects in people. The material sold here is a research reagent.

Yes. Retatrutide is a synthetic 39-amino-acid peptide that includes several non-standard amino acids, such as α-aminoisobutyric acid (Aib), and carries a C20 fatty diacid side chain attached through a linker. The fatty-acid chain binds albumin, which extends the molecule's persistence in research systems. Identity and purity of each lot are confirmed by HPLC and mass spectrometry on the Certificate of Analysis.

Retatrutide is the compound's international nonproprietary name, and LY3437943 is Eli Lilly's development code. Because it is not an approved medicine, it has no brand name. Researchers and suppliers often shorten it to "reta", and it is sometimes informally called a "triple agonist" or "GLP-3" because it acts on three receptors.

Partly. Retatrutide activates the GLP-1 receptor, but it also activates the GIP receptor and the glucagon receptor, so it is classed as a triple agonist rather than a GLP-1 agonist alone. The informal name "GLP-3" refers to those three receptor targets; there is no hormone called GLP-3.

All three are fatty-acid-modified synthetic peptides studied in incretin research, and they differ mainly in receptor targets. Semaglutide (Novo Nordisk) activates the GLP-1 receptor only. Tirzepatide (Eli Lilly) activates the GIP and GLP-1 receptors. Retatrutide (Eli Lilly) activates the GIP, GLP-1 and glucagon receptors. Semaglutide and tirzepatide are FDA-approved active ingredients; retatrutide is investigational and not FDA approved as of October 2026. All three are sold here as research reagents.

Not as a medicine. As of October 2026 retatrutide is investigational and has not been approved by the FDA, so it cannot be prescribed or sold as a drug in the United States. It is supplied by chemical vendors, including us, as a research reagent for laboratory use only, not for human or veterinary use.

Keep sealed, lyophilized retatrutide cold, dry and dark: refrigerated at 2–8 °C for short-term storage, or frozen at −20 °C or below for long-term storage. Let the vial reach room temperature before opening so moisture does not condense on the powder. After reconstitution, keep the solution refrigerated and avoid repeated freeze-thaw cycles.

They are unrelated peptides with different targets. Retatrutide is a 39-amino-acid, fatty-acid-modified triple agonist of the GIP, GLP-1 and glucagon receptors, and is investigational. Tesamorelin is a 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) with an N-terminal trans-3-hexenoyl group; it acts on the GHRH receptor and is an FDA-approved active ingredient. Both are sold here as research reagents.

No. Ara-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin and studied in relation to the innate repair receptor. Retatrutide is a 39-amino-acid, fatty-acid-modified agonist of the GIP, GLP-1 and glucagon receptors. They share no sequence, target or developer; the two names simply appear together in some searches.

They are different classes of molecule. 5-Amino-1MQ is a small quinolinium compound that inhibits the enzyme NNMT inside cells. Retatrutide is a 39-amino-acid, fatty-acid-modified peptide that activates three cell-surface receptors (GIP, GLP-1 and glucagon). 5-Amino-1MQ is not a GLP-1 agonist and does not act on incretin receptors.

No. MOTS-c is a 16-amino-acid mitochondrial-derived peptide and has no sequence relationship to GLP-1. It is studied in connection with the AMPK pathway rather than incretin receptors. Retatrutide, tirzepatide and semaglutide, by contrast, are fatty-acid-modified peptides designed to activate the GLP-1 receptor (and, for the first two, the GIP and, for retatrutide, glucagon receptors).

They are entirely different designs. Adipotide is a peptidomimetic built to bind prohibitin on blood vessels of white adipose tissue and carry a membrane-disrupting D-amino-acid sequence. Retatrutide, like tirzepatide and semaglutide, is a fatty-acid-modified incretin receptor agonist that activates hormone receptors (GIP, GLP-1 and glucagon for retatrutide). Adipotide does not act on these receptors.

Retatrutide: CAS number 2381089-83-2. Match these identifiers against the Certificate of Analysis for the lot.

Yes. Each lot has its own Certificate of Analysis, linked on this page for the current lot of each size: 5mg (99.45% HPLC purity); 20mg (99.48% HPLC purity); 60mg (99.42% HPLC purity). Past certificates are archived in the COA library; contact us with the lot number on the vial label if a certificate is missing.

99.42% (HPLC, current lot). Purity is measured by high-performance liquid chromatography (HPLC) and reported on the lot's Certificate of Analysis.

Retatrutide is supplied as lyophilized powder in a sealed vial in 3 sizes: 5mg, 20mg, 60mg. In stock and dispatched in 1–2 business days. Quantity pricing applies automatically at 5+ and 10+ vials of the same size.

Store sealed at −20 °C, dry and protected from light.